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Epidemiologic studies have shown associations
between asthma outcomes and criteria air pol-
lutants regulated by the U.S. Environmental
Protection Agency (EPA), such as nitrogen
dioxide and mass concentrations of particulate
matter (PM) < 2.5 µm in aerodynamic diame-
ter (PM2.5). It is unclear whether these associa-
tions for pollutant gases and particles are
independent of each other or are attributable to
toxic air pollutants not routinely monitored,
such as combustion-related organic compounds
(Delfino 2002). Growing experimental evi-
dence suggests that PM organic components,
including polycyclic aromatic hydrocarbons
(PAHs), have adjuvant effects on cytokine-
mediated airway inﬂammation, at least partly
through exposure to redox active chemicals and
resultant oxidative stress (Li et al. 2003). The
relevance of these findings to people with
asthma can be enhanced with an assessment of
the impact of personal air pollutant exposures
on acute changes in asthma outcomes.
Children with asthma at greatest risk of exacer-
bations from air pollutants likely include those
with persistent asthma symptoms.
Airway inflammation is a hallmark of
asthma. The fractional concentration of nitric
oxide in exhaled air (FENO) is a noninvasive
biomarker of airway inflammation and is
higher in subjects with poorly controlled
asthma (Jones et al. 2001). Therefore, FENO is
potentially useful in epidemiologic field
research to evaluate the impacts of air pollution
on the inﬂammatory state of airways in chil-
dren with asthma. NO is produced endoge-
nously in the airways from L-arginine by NO
synthetase. There are two constitutive isoforms
and an inducible isoform involved in airway
inflammation. Inflammatory cytokines (e.g.,
tumor necrosis factor-α) increase the expression
of inducible NO synthetase in airway epithe-
lium (Zeidler et al. 2004). There is extensive
evidence that FENO is elevated in patients with
untreated asthma and decreases with corticos-
teroid treatment (Zeidler et al. 2004; Zeiger
et al. 2006). There is also evidence that FENO
correlates with eosinophilic inflammation in
asthmatic patients, especially in atopic subjects
(Zeidler et al. 2004). After withdrawal of
inhaled steroids, FENO accurately predicts loss
of asthma control (positive predictive value
80–90%) just as well as either eosinophils from
induced sputum or bronchial hyperresponsive-
ness (Jones et al. 2001).
We examined the relationship of daily
FENO with personal and ambient air pollution
exposures in 45 schoolchildren with asthma.
We hypothesized that airway inﬂammation in
asthmatic children as measured by FENO
would be positively associated with personal
exposure to PM2.5, elemental and organic car-
bon fractions of PM2.5 (EC and OC), and
NO2. We further aimed to determine whether
EC, OC, or NO2 is more strongly and pre-
cisely associated with FENO than PM2.5 mass.
By measuring personal particle exposures, we
aimed to conﬁrm and clarify our earlier ﬁnd-
ings that associations of asthma symptoms
with ambient mass concentrations of PM
< 10 µm in aerodynamic diameter (PM10)
were better explained by EC and OC fractions
of ambient PM10 (Delﬁno et al. 2003). In that
panel study, 20 Hispanic children with asthma
were followed daily over 24 days in a small Los
Angeles (LA) community surrounded by free-
ways. A positive association of asthma symp-
toms with PM10 was reduced to unity when
Address correspondence to R.J. Delﬁno, Epidemiology
Division, Department of Medicine, School of
Medicine, University of California, Irvine, 100
Theory, Suite 100, Irvine, CA 92617-7555 USA.
Telephone: (949) 824-1767. Fax: (949) 824-1343. 
E-mail: rdelﬁno@uci.edu
Supplemental Material is available online at
http://www.ehponline.org/docs/2006/9141/suppl.pdf
We thank the staff at the General Clinical
Research Center, University of California, Irvine,
and the South Coast Air Quality Management
District (SCAQMD). 
The project described was supported by grant
ES11615 from the National Institute of
Environmental Health Sciences (NIEHS), National
Institutes of Health (NIH), and its contents are
solely the responsibility of the author and do not
necessarily represent the ofﬁcial views of the NIEHS.
Support for exhaled nitric oxide measurements was
provided by SCAQMD, through the University of
California, Los Angeles, Asthma and Outdoor Air
Quality Consortium (Contract UCLA-35692). The
contents of this paper and the ﬁndings of its authors
do not necessarily reﬂect the views of the SCAQMD
that has not approved or disapproved this report. 
The authors declare they have no competing
ﬁnancial interests.
Received 3 March 2006; accepted 11 July 2006.
Personal and Ambient Air Pollution is Associated with Increased Exhaled
Nitric Oxide in Children with Asthma
Ralph J. Delﬁno,1 Norbert Staimer,1 Dan Gillen,2 Thomas Tjoa,1 Constantinos Sioutas,3 Kochy Fung,4
Steven C. George,5 and Michael T. Kleinman6
1Epidemiology Division, Department of Medicine, School of Medicine, University of California, Irvine, Irvine, California, USA;
2Department of Statistics, University of California, Irvine, Irvine, California, USA; 3Department of Civil and Environmental Engineering,
School of Engineering, University of Southern California, Los Angeles, California, USA; 4AtmAA, Inc., Calabasas, California, USA;
5Department of Biomedical Engineering, University of California, Irvine, Irvine, California, USA; 6Department of Community and
Environmental Medicine, School of Medicine, University of California, Irvine, Irvine, California, USA
BACKGROUND: Research has shown associations between pediatric asthma outcomes and airborne
particulate matter (PM). The importance of particle components remains to be determined. 
METHODS: We followed a panel of 45 schoolchildren with persistent asthma living in Southern
California. Subjects were monitored over 10 days with offline fractional exhaled nitric oxide
(FENO), a biomarker of airway inﬂammation. Personal active sampler exposures included continu-
ous particulate matter < 2.5 µm in aerodynamic diameter (PM2.5), 24-hr PM2.5 elemental and
organic carbon (EC, OC), and 24-hr nitrogen dioxide. Ambient exposures included PM2.5, PM2.5
EC and OC, and NO2. Data were analyzed with mixed models controlling for personal temperature,
humidity and 10-day period. 
RESULTS: The strongest positive associations were between FENO and 2-day average pollutant con-
centrations. Per interquartile range pollutant increase, these were: for 24 µg/m3 personal PM2.5,
1.1 ppb FENO [95% conﬁdence interval (CI), 0.1–1.9]; for 0.6 µg/m3 personal EC, 0.7 ppb FENO
(95% CI, 0.3–1.1); for 17 ppb personal NO2, 1.6 ppb FENO (95% CI, 0.4–2.8). Larger associa-
tions were found for ambient EC and smaller associations for ambient NO2. Ambient PM2.5 and
personal and ambient OC were significant only in subjects taking inhaled corticosteroids (ICS)
alone. Subjects taking both ICS and antileukotrienes showed no significant associations.
Distributed lag models showed personal PM2.5 in the preceding 5 hr was associated with FENO. In
two-pollutant models, the most robust associations were for personal and ambient EC and NO2,
and for personal but not ambient PM2.5.
CONCLUSION: PM associations with airway inflammation in asthmatics may be missed using
ambient particle mass, which may not sufﬁciently represent causal pollutant components from fos-
sil fuel combustion. 
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of PM10, but larger positive associations of EC
and OC with symptoms remained stable. This
finding suggests that combustion-related
organic compounds such as those in diesel
exhaust are causally related to acute asthma.
EC and OC may have represented particle
components (e.g., PAHs) and key sources that
are believed to play a causal role (Li et al.
2003). As crude markers of pollutant sources,
EC primarily represents products of fossil fuel
combustion in the LA Basin, especially diesel
exhaust, and OC represents both fossil fuel
combustion and secondary organic aerosols
(Fine et al. 2004; Schauer et al. 2002).
Similarly, NO2 is strongly inﬂuenced by local
trafﬁc density (Kim et al. 2004; Roorda-Knape
et al. 1999), and it may serve as a surrogate for
particulate air pollutants more causally related
to acute changes in asthma morbidity.
Therefore, we also aimed to determine whether
personal or ambient PM2.5, EC, or OC expo-
sures interact with or confound personal or
ambient NO2 in relation to FENO. 
Materials and Methods
Design and population. This panel study
involves repeated daily measurements of health
outcomes and exposures in children with
asthma. It was conducted in urban regions of
Southern California with high levels of air pol-
lution, primarily from mobile sources of fossil
fuel combustion. The first region was in
Riverside, California, where subjects were fol-
lowed from August through mid-December
2003. This is a downwind smog receptor site
just inland from LA County. The second
region was in Whittier, California, in eastern
LA County, where subjects were followed from
July through November 2004. Data reported in
this article are from an intensive phase of study
over 10-day periods. This involved having sub-
jects wear an active personal monitor to meas-
ure exposure to air pollutants, and collection of
an off-line measurement of FENO at the end of
each 24 hr of personal sampling. Data for both
FENO and personal air pollutant exposures were
collected from 48 asthmatic children (16 from
Riverside) over twelve 10-day periods, four sub-
jects per period. Subjects were followed daily in
their homes to check the validity of exposure
and outcome data and to ensure compliance.
Each subject completed a diary on personal dig-
ital assistants every two waking hours.
Questions addressed preventive medication use
and respiratory infections. Missed prompts
were mitigated with paper diaries and daily
technician-administered questionnaires. 
The institutional review board of the
University of California, Irvine (UCI)
approved the study protocol. Informed written
assent was obtained from subjects and consent
was obtained from one of their legal guardians.
Subjects who were 9–18 years of age were
recruited through notification of parents by
public schools. We targeted subjects with per-
sistent asthma having a history in the previous
12 months of exacerbations of asthma symp-
toms requiring the use of as-needed broncho-
dilators ≥ 2 days/week, or taking oral or
inhaled anti-inflammatory medications,
regardless of recent symptom frequency.
Finally, subjects were recruited with < 80%
predicted forced expiratory volume in 1 sec
(FEV1) from baseline spirometry. Subjects
were ineligible if they smoked or if someone
smoked in the subject’s home. 
Measurement of exhaled NO. We meas-
ured exhaled NO using recommended proce-
dures [American Thoracic Society/European
Respiratory Society (ATS/ERS) 2005], with
modiﬁcations suggested by Linn et al. (2004)
and Kroesbergen et al. (1999). The method
involved collection of exhalate into receptacles
for later chemical analysis. Subjects were asked
to refrain from performing spirometry, exer-
cise, and food or beverage intake 1 hr before
sample collection. Subjects inhaled orally to
total lung capacity and then immediately per-
formed a slow vital capacity maneuver into an
offline apparatus attached to a nonreactive
1.5-L Mylar reservoir bag (Ionics Inc.,
Boulder, CO). The flow rate was to be 100
mL/sec at all times by maintaining pressure at
19 cm H2O, which is suitable for children
with asthma (Kroesbergen et al. 1999).
Approximately 200 mL of dead-space air was
vented before the bag sample was collected, to
reduce contamination from the upper airways
(Jobsis et al. 2001). To control for inspired
ambient NO, an NO/NO2 chemisorbent ﬁlter
was placed at the air intake of the ofﬂine appa-
ratus, and subjects breathed through it for 15
sec (≥ 2 tidal breaths) before sampling. Two
breath samples were collected to assess reliabil-
ity. The 10 daily collections were done at the
same time of day for each subject. An indoor
air sample was collected to assess inﬂuence of
indoor NO on FENO despite use of the NO
scrubbing ﬁlter (ATS/ERS 2005). Mylar bags
were sealed, refrigerated at 6°C, and analyzed
within 20 hr for FENO concentration with a
chemiluminescence NO analyzer (NOA 280i
Sievers; GE Analytical Instruments, Boulder,
CO). We retained for analysis the mean of
FENO pairs where differences were ≤ 3 ppb or
≤ 10% of the larger reading. 
Exposures. Our personal exposure monitor
was constructed to collect 24-hr samples of per-
sonal PM2.5, EC and OC fractions of PM2.5,
NO2, temperature, and relative humidity
(RH). Each subject wore the monitor during
waking hours in a backpack. Personal PM2.5
monitors operated at 4 L/min with the sam-
pling inlet near the breathing zone. One-
minute average PM2.5 was measured using an
integrated nephelometer, the personal
DataRAM model 1200 (pDR; MIE Inc.,
Bedford, MA). Compliance (motion), RH, and
temperature loggers recorded at 1-min intervals
(Onset Computer Corp., Pocasset, MA). Data
were downloaded and checked for quality and
compliance daily. pDR data were adjusted for
personal RH (Chakrabarti et al. 2004). The
pDR conﬁguration also included a ﬁlter car-
tridge for EC and OC. A 2.5-µm sharp-cut
cyclone was attached upstream of the pDR, and
PM2.5 was collected on 37-mm quartz ﬁlters
(Whatman Inc., Florham Park, NJ). The per-
sonal PM2.5 monitor was validated by our
group in a previous report and it is described in
detail there (Chakrabarti et al. 2004). 
We developed an active sampling system
for NO2 that ran in parallel with the pDR. It
uses a miniaturized diaphragm pump (Virtual
Industry VMP1625, Colorado Springs, CO)
run at 0.1 L/min, and triethanolamine-treated
molecular sieve sorbent tubes as a collection
medium (SKC West Inc., Fullerton, CA). NO2
measurements were based on National Institute
for Occupational Safety and Health method
6014 (National Institute for Occupational
Safety and Health 1994). This personal NO2
exposure monitor was validated by our group in
a previous report and it is described in detail
there (Staimer et al. 2005). 
Central-site ambient exposures included
24-hr PM2.5, PM10, and PM2.5 EC and OC
collected from early evening to early evening
with Harvard Impactors (Air Diagnostics and
Engineering, Inc., Naples, ME) using standard
procedures. After sample collection on quartz
filters, particulate carbon was speciated into
OC and EC using the thermal manganese
dioxide oxidation technique (for details, see
Fung et al. 2002). EC and OC are expressed as
amount of total carbon per sample. Central-
site data also included hourly ozone, NO2, and
CO measured by the South Coast Air Quality
Management District. In Riverside, the district
site was centrally located. In Whittier, we con-
structed a central site at a subject home ele-
vated on a hill. Data for O3, NO2, and CO
came from two district sites at opposite ends of
the Whittier study region (La Habra and Pico
Rivera). Hourly concentrations for the two
stations were averaged.
Statistical methods. We used linear mixed-
effects models (Verbeke and Molenberghs
2001) to estimate the association between each
air pollutant and FENO. Because the data repre-
sent repeated measures on individuals over time,
correlation among outcomes was present. We
assumed a two-stage hierarchical model with
random effects at the subject level, nested within
exposure run. Empirical variograms (graphical
measures of the correlation between observa-
tions as a function of time) showed an auto-
regressive-1 correlation structure adequately
described the observed variability. All exposures
were mean-centered by individual to obtain
comparability from one participant location to
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exposures preceding the FENO measurement
including the last 24 hr (lag 0), the average of
the 25th through 48th hour preceding the
FENO measurement (lag 1), and a cumulative
2-day moving average (2-day MA). Results are
expressed as ppb change in FENO per inter-
quartile range (IQR) increase in pollutant.
Given their potential for confounding
associations, we decided a priori that personal
temperature, personal RH, and 10-day expo-
sure run should be adjusted for in all models.
We also tested potential confounding by respi-
ratory infections, region of study, sex, cumula-
tive daily use of as-needed β-agonist inhalers,
and weekend. None of these variables con-
founded associations, and there was no air pol-
lutant interaction with sex or respiratory
infection (only 13 person-days reported).
Secondary analyses examining potential effect
modiﬁcation by medication use were also con-
ducted. Residual diagnostics were conducted
for all models to investigate the presence of
influential data points and deviations from
assumed functional form. No data points were
removed for inﬂuence. As a validity check to
the likelihood assumptions made by the linear
mixed-effects model, regression models using
generalized estimating equations (Diggle et al.
2002) in combination with robust standard
error estimates were also ﬁt. No qualitative dif-
ferences in our study results were found.
To investigate the lag effect of hourly per-
sonal PM2.5 on FENO, we used a fourth-order
polynomial distributed lag mixed-effects model
(Schwartz 2000). An autoregressive correlation
structure was assumed and supported by resid-
ual diagnostics. Distributed lag models stratify-
ing on anti-inﬂammatory medication use were
also ﬁt.
Between-pollutant confounding was tested
with two-pollutant regression models. We
compared the change in regression parameters
from single- to two-pollutant models for the
same subset of nonmissing person-days for
both pollutants. Interaction between pollutants
was tested first in a regression equation with
the two pollutant variables and their product
term as predictors.
Results
Descriptive subject data. The Riverside panel
included eight 10-day runs with four subjects
per run. However, the Sievers NO Analyzer
malfunctioned after the third day of run 5.
The analyzer was replaced by a new one, but
not until after the end of Riverside run 8. In
addition, personal samplers malfunctioned
during most of the entire first run for three
subjects. This was resolved before the next run.
Therefore, we retained for analysis data from
the ﬁrst four 10-day runs in Riverside involv-
ing 13 subjects. Data were collected for all
Delfino et al.
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Table 3. Daily air measurements stratiﬁed by study panel. 
Riverside panel (n = 13) Whittier panel (n = 32)
Exposure No. (missing) Mean ± SD Median IQR Min/max No. (missing) Mean ± SD Median IQR Min/max
Personal exposure
24-hr PM2.5 (µg/m3) 98 (11) 32.78 ± 21.84 28.14 28.41 7.27/98.43 250 (13) 36.2 ± 25.46 29.07 21.87 7.55/197.05
1-hr max PM2.5 (µg/m3) 95 (14) 97.94 ± 70.29 83.7 86.75 14.9/431.8 238 (25) 93.63 ± 75.19 71.95 67.67 15.8/572.9
8-hr max PM2.5 (µg/m3) 95 (14) 47.21 ± 30.9 38.5 45.4 8.9/132.1 238 (25) 51.75 ± 36.88 40.15 33.5 8.7/254.1
24-hr PM2.5 EC (µg/m3) 100 (9) 0.42 ± 0.69 0.34 0.32 0.01/6.94 246 (17) 0.78 ± 1.42 0.47 0.8 0/17.2
24-hr PM2.5 OC (µg/m3) 100 (9) 5.63 ± 2.59 4.98 3.36 1.94/12.38 251 (12) 6.81 ± 3.45 6.43 3.97 2.18/31.5
24-hr NO2 (ppb) 107 (2) 24.26 ± 9.34 24.31 11.69 5.16/47.61 261 (2) 30.89 ± 14.59 28.5 18.7 2.7/105.7
24-hr temperature 106 (3) 79.88 ± 3.75 79.06 6.14 73.13/88.35 261 (2) 76.55 ± 4.89 77.57 6.86 63.22/86.94
Central site (PM; µg/m3)
24-hr PM2.5 109 (0) 36.63 ± 23.46 29.26 30.83 9.52/87.22 252 (11) 18 ± 12.14 16.3 8.67 2.77/77.09
24-hr PM10 109 (0) 70.82 ± 29.36 65.96 40.38 30.75/154.05 251 (12) 35.73 ± 16.6 34.65 17.97 5.86/105.46
24-hr PM2.5 EC 94 (15) 1.61 ± 0.78 1.35 0.91 0.52/3.64 251 (12) 0.71 ± 0.43 0.63 0.44 0.14/2.95
24-hr PM2.5 OC 94 (15) 6.88 ± 1.86 6.07 2.19 4.11/11.62 251 (12) 3.93 ± 1.49 3.76 2.04 1.64/8.82
Central site (gases; ppb)
8-hr max O3 109 (0) 76.37 ± 18.47 73.62 18.62 33.38/120.75 263 (0) 40.56 ± 14.12 38.94 18.1 11.06/79.25
8-hr max NO2 109 (0) 39.27 ± 14.6 38 16.14 17.75/72.43 256 (7) 35.05 ± 13.41 30 14.63 13.44/96
24-hr NO2 109 (0) 27.18 ± 5.56 24.01 12.15 21.29/34.78 263 (0) 28.07 ± 4.83 29.69 6.22 18.81/35.4
8-hr max CO 109 (0) 530.6 ± 369.58 442.86 514.29 0/1342.86 263 (0) 863.85 ± 523.1 700 600 275/2492.86
Abbreviations: max, maximum; min, minimum.
Table 1. Study group characteristics, Riverside and Whittier, California, asthma panels.
Subject variable Data
Age [years, mean (range)] 13.5 (9–18)
Sex [no. (%)]
Female 14 (31)
Male 31 (69)
Race [no. (%)]
Hispanic 26 (58) 
White  14 (31) 
Black  5 (11) 
No. (%) with mean percent FEV1 < 80%a 11 (24)
Asthma exacerbation previous 12 months required hospital admission, ED visit, or clinic visit
0 times 12 (27)
1–4 times 19 (42)
> 4 times 14 (31)
aPredicted from NHANES III (Hankinson et al. 1999) using 2 months of thrice daily home spirometry, acceptable and repro-
ducible maneuvers. 
Table 2. Distribution of FENO (ppb) by region and medication use.
Variable Mean ± SD Median 25–75th percentile Range 
Overall (45 subjects) 25.6 ± 25.1  18.2 10.5–32.0 2.7–154
Region
Riverside (13 subjects) 16.6 ± 11.1  13.6 8.8–18.8 3.4–48.5
Whittier (32 subjects) 29.4 ± 28.1a 20.8 10.5–33.3 2.7–154
Medication group
No anti-inﬂammatory medication (14 subjects) 35.9 ± 35.8 23.9 11.8–46.6 5.0–154
Anti-inﬂammatory medication (31 subjects) 21.1 ± 16.8b 17.5 9.9–26.2 2.7–98.4
Anti-inﬂammatory medication group
Inhaled corticosteroids (19 subjects)c 20.4 ± 19.5 16.0 6.7–22.1 2.7–98.4
Antileukotrienes ± inhaled corticosteroids (12 subjects)d 22.4 ± 10.7e 19.6 14.5–30.7 5.0–51.4
aRandom-effects model p = 0.16 for FENO difference from Riverside. bRandom-effects model p = 0.06 for FENO difference
from no anti-inflammatory medication. cTwo subjects were also taking inhaled cromolyn. dTwo subjects were taking
antileukotrienes only, and 10 were taking antileukotrienes plus inhaled corticosteroids; mean FENO for the two subjects
taking antileukotriene medications alone was 21.0 ± 9.1 ppb. eRandom-effects model p = 0.66 for FENO difference from
inhaled corticosteroids.eight 10-day runs in Whittier for 32 subjects
and combined with data from Riverside.
Table 1 shows characteristics of the 45 subjects. 
Of 446 daily pairs of FENO samples, we
found that 372 pairs (83%) were reliable by our
criteria (≤ 3 ppb NO or ≤ 10% difference). In
the Supplemental Material (http://www.
ehponline.org/docs/2006/9141/suppl.pdf), we
present analyses of relationships of FENO with
the quality of maneuver and noncompliance
with pretesting spirometry, exercise, food, and
beverages. Controlling for maneuver quality
and noncompliance factors did not confound
the associations of FENO with air pollutants. In
addition, there was no relationship between
indoor NO and acceptable FENO pairs (slope
0.04 ± 0.03, p = 0.21), and indoor NO concen-
tration did not inﬂuence associations of air pol-
lutant exposures with FENO. 
The distribution of FENO concentrations by
region and medication use is shown in Table 2.
Subjects in Whittier had nonsignificantly
higher FENO than did Riverside subjects. As
conﬁrmed in daily diaries and by research staff,
14 subjects were not taking anti-inﬂammatory
controller medications and 31 were [inhaled
corticosteroids (ICS) and antileukotrienes
(leukotriene receptor antagonists zaﬁrlukast and
montelukast)]. Subjects not taking any anti-
inflammatory medication had higher mean
FENO, consistent with expectations (Zeidler
et al. 2004). There was no difference within the
anti-inﬂammatory medication group by use of
antileukotrienes.
Descriptive exposure data. Table 3 shows
descriptive data for exposures by region.
Central-site particle mass, EC, OC, NO2, and
O3 concentrations were higher in Riverside
because this warmer receptor region is located
downwind of major urban sources in LA,
adding to local sources of these air pollutants.
Despite lower ambient concentrations, per-
sonal EC, OC, and NO2 were somewhat
higher in Whittier than in Riverside, perhaps
reflecting proximity of subjects to densely
populated LA areas having a higher local trafﬁc
impact. Maximum 1-hr personal PM2.5 ranged
up to 573 µg/m3. 
Table 4 shows the between-pollutant cor-
relations. Correlations of personal PM2.5 with
personal EC, OC, and NO2 were signiﬁcant
but small, and not much different from corre-
lations with ambient data. Personal EC and
OC were not correlated with ambient EC and
OC but were correlated with ambient NO2.
Personal PM2.5 was moderately correlated
with ambient PM2.5 (r = 0.64), and personal
NO2 was moderately correlated with ambient
NO2 (r = 0.46). Ambient exposures were all
moderately correlated with each other. 
Regression models for personal as compared
with central-site air pollutants. We found
positive associations of FENO with increasing
personal PM2.5 mass, EC, and NO2, and
central-site EC, OC, and NO2 (Table 5). The
most robust associations [largest coefficient
and/or tightest 95% conﬁdence interval (CI)]
were between FENO and 2-day average expo-
sures for all regression models. Exhaled NO was
associated with personal PM2.5, but was not
associated with ambient PM2.5 (p > 0.22) or
ambient PM10 (not shown). Except for lag 0
EC, the associations of FENO with EC and OC
were stronger for central-site than for personal
measurements, but 95% CIs overlapped exten-
sively and lower bounds for all of the OC mod-
els were negative. The association of FENO with
personal and central-site 2-day average NO2
was similar. There was little difference in associ-
ations using 8-hr maximum central-site NO2
(not shown). Ambient CO and O3 were not
associated with FENO (not shown). Including
74 person-days of sampling with the means of
the unreliable FENO pairs did not alter strengths
of association but SEs increased as expected.
The exception was for 2-day MA personal
PM2.5, where the parameter estimate decreased
from 0.041 ± 0.019 to 0.030 ± 0.020.
Differences in association by medication
use. Table 6 shows results for models stratiﬁed
by medication use. We found associations with
personal NO2, and ambient EC, OC, and
NO2 were stronger and more signiﬁcant in the
group on anti-inﬂammatory medications than
in the group not on anti-inﬂammatory medica-
tions. However, product terms for these pollu-
tants by a medication group indicator were not
signiﬁcant at p < 0.1. The anti-inﬂammatory
medication group was next split into subjects
only taking ICS and subjects taking anti-
leukotrienes with or without ICS. Results sug-
gest effect modification by antileukotrienes
combined with ICS. Among the group taking
ICS but not antileukotrienes, all air pollutants
were significantly associated with FENO, or
nearly so in the case of ambient PM10.
Personal and ambient OC and ambient PM2.5
were signiﬁcantly associated with FENO only in
the group taking ICS but not antileukotrienes.
Product terms for controller medication group
by personal PM2.5 and by ambient PM2.5 and
PM10 were all signiﬁcant. We found no mean-
ingful change in the null results dropping two
of the 12 subjects taking antileukotrienes who
were not also taking ICS.
Distributed lag models for hourly personal
PM2.5. Figure 1 shows that FENO in all 45
subjects is acutely associated with PM2.5 expo-
sure in the 5 hr preceding measurement, with
the lower 95% confidence bound crossing
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Table 4. Exposure correlation matrix (both study panels pooled).
Personal Central
PM2.5 EC OC NO2 PM2.5 EC OC NO2
24-hr personal PM2.5 1.00 0.18** 0.15* 0.33** 0.64** 0.12* 0.21** 0.22**
24-hr personal EC 1.00 0.41** 0.21** 0.00 0.04 –0.01 0.23**
24-hr personal OC 1.00 0.20** –0.11* 0.03 –0.02 0.21**
24-hr personal NO2 1.00 0.12* 0.19** 0.17* 0.46**
24-hr central PM2.5 1.00 0.55** 0.66** 0.25**
24-hr central EC 1.00 0.87** 0.70**
24-hr central OC 1.00 0.62**
24-hr central NO2 1.00
*p-value < 0.05; **p-value < 0.001 from Wald-based tests of Spearman correlation coefﬁcients.
Table 5. Mixed-model estimates of the association between personal and central-site air pollutant expo-
sure and FENO.
Personal Central site
Exposure Coefﬁcienta (95% CI) p-Value Coefﬁcient (95% CI) p-Value
PM2.5
Lag 0 0.42 (–0.15 to 0.99) 0.148 0.03 (–0.68 to 0.74) 0.925
Lag 1 0.51 (–0.10 to 1.12) 0.100 0.44 (–0.28 to 1.16) 0.226
2-day MA 1.01 (0.14 to 1.88) 0.024 0.52 (–0.43 to 1.47) 0.287
PM2.5 EC
Lag 0 0.29 (0.10 to 0.48) 0.003 0.10 (–0.65 to 0.85) 0.793
Lag 1 –0.01 (–0.23 to 0.21) 0.898 0.99 (0.27 to 1.71) 0.007
2-day MA 0.72 (0.32 to 1.12) 0.001 1.38 (0.15 to 2.61) 0.027
PM2.5 OC
Lag 0 0.51 (–0.28 to 1.30) 0.207 0.93 (–0.20 to 2.06) 0.104
Lag 1 0.13 (–0.77 to 1.03) 0.768 0.51 (–0.64 to 1.66) 0.386
2-day MA 0.94 (–0.47 to 2.35) 0.190 1.6 (–0.17 to 3.37) 0.077
NO2
Lag 0 0.25 (–0.44 to 0.94) 0.471 0.10 (–0.55 to 0.75) 0.752
Lag 1 0.60 (–0.12 to 1.32) 0.103 0.72 ( 0.08 to 1.36) 0.028
2-day MA 1.63 (0.43 to 2.83) 0.008 1.36 ( 0.39 to 2.33) 0.006
CI, conﬁdence interval. Lag 0: 24-hr average preceding the FENO measurement; Lag 1: average for the 25th through 48th hr
preceding the FENO measurement; 2-day MA: moving average for the 48 hr preceding the FENO measurement.
aThe expected change in FENO associated with one IQR change in each air pollutant level, adjusted for personal tempera-
ture, personal relative humidity, and run. IQRs for personal air pollutant measurements were 24 µg/m3 for PM2.5, 0.6 µg/m3
for PM2.5 EC, 4.1 µg/m3 for PM2.5 OC, and 17 ppb for NO2. IQRs for central-site air pollutant measurements were 15 µg/m3 for
PM2.5, 0.8 µg/m3 for PM2.5 EC, 2.9 µg/m3 for PM2.5 OC, and 12 ppb for NO2.zero after lag 5 and coefﬁcients remaining near
zero after that. Beyond 24 hr, we found no
significant association between PM2.5 and
FENO, partly because of the high variability
resulting from such large lag times. The associ-
ations are stronger the closer the personal
PM2.5 measurement is to the FENO measure-
ment. At lag 0 hr, FENO was estimated to
increase 0.46 ppb (95% CI, 0.13–0.78)
per one-IQR increase in personal PM2.5
(24 µg/m3). 
Figure 2 shows that associations of FENO
with lag 0–5 hr personal PM2.5 were moder-
ately stronger in the group not on anti-inﬂam-
matory medications. At lag 0 hr, FENO
increased 0.57 ppb (95% CI, –0.06 to 1.20)
per IQR increase in personal PM2.5 (24 µg/m3)
among subjects not taking anti-inﬂammatory
medications (Figure 2A), compared to 0.35
ppb (95% CI, –0.02 to 0.71) among subjects
taking anti-inﬂammatory medications (Figure
2B). When the medication group was further
divided based on use of antileukotrienes, we
found an early association between PM2.5 and
FENO among patients taking only inhaled cor-
ticosteroids (Figure 2C). At lag 0 hr, FENO
increased by 0.53 ppb (95% CI, 0.06–1.00),
but there was no association among patients on
antileukotrienes (Figure 2D), consistent with
results using the 2-day MA.
We also tested models for the relationship
between FENO and 1-hr and 8-hr maximum
personal PM2.5 in the previous 24 hr (not
shown). We found that for all 45 subjects, an
IQR increase of 73 µg/m3 1-hr maximum per-
sonal PM2.5 was associated with a 0.60-ppb
increase in FENO (95% CI, 0.14–1.05). Eight-
hour maximum personal PM2.5 (37 µg/m3)
was similarly associated with FENO (0.54 ppb;
95% CI, 0.09–1.16). We found a stronger
association between FENO and 1-hr maximum
personal PM2.5 in subjects not taking anti-
inﬂammatory medications (1.36 ppb, 95% CI,
0.07–2.79) compared with those taking them
(0.46 ppb; 95% CI, 0.05–0.87), but the differ-
ence was not signiﬁcant (p = 0.14). 
Two-pollutant models. The only signifi-
cant interaction between air pollutants tested
in the two-pollutant models was a positive
interaction between personal PM2.5 and per-
sonal OC (p = 0.003). Figure 3 shows models
for personal exposures and separately for
ambient exposures. For personal two-pollutant
models, the most robust association was for
EC, followed by NO2, PM2.5, and then OC.
For two-pollutant models using ambient data,
we found CIs widened for both pollutants,
partly due to their correlation (Table 3). Co-
regression of ambient PM2.5 with ambient
EC, OC, or NO2 led to a large reduction in
the parameter for PM2.5 to near zero, but little
change in estimates of association for EC, OC,
or NO2. Ambient OC was markedly con-
founded by both NO2 and EC. Overall, the
ambient two-pollutant models show the most
robust association for NO2 and EC. 
To assess whether the association of FENO
in all 45 subjects with ambient EC or NO2
was independent of personal EC or NO2, we
co-regressed two-day average ambient with
personal EC (not correlated; Table 4), and
personal with ambient NO2 (moderately cor-
related). Associations for personal and central-
site EC were completely stable compared with
single-pollutant models (Table 5) [0.73 ppb
(95% CI, 0.30–1.15) and 1.37 ppb (95% CI,
0.13–2.60), respectively]. Personal NO2 com-
pletely confounded ambient NO2 [1.46 ppb
(95% CI, –0.24 to 3.16) and 0.19 ppb (95%
CI, –1.24 to 1.62), respectively]. 
To assess whether the positive association
of FENO in 19 subjects on ICS with ambient
PM2.5 or OC was independent of personal
PM2.5 or OC, we co-regressed ambient with
personal exposures for the same pollutant. The
association with ambient PM2.5 was com-
pletely confounded by personal PM2.5, which
showed nearly the same positive association
with FENO as the single-pollutant model in
Table 6. The between-pollutant correlation
was 0.53. Similarly, the association with ambi-
ent OC was halved, whereas personal OC was
minimally reduced by 13%. The between-
pollutant correlation was nonsigniﬁcant. The
isolated association of ambient PM2.5 with
FENO in this group was independent of
ambient EC, OC, and NO2.
Discussion
Positive associations were found for FENO in
relation to personal and ambient air pollutants,
with evidence from the multiple-pollutant
approach that trafﬁc-related sources of air pol-
lutants underlie the findings. Although the
estimates of effect were small (≤ 2.5 ppb
FENO), inasmuch as FENO is a marker of airway
inﬂammation, this would suggest that air pol-
lution increases inﬂammation. We cannot say
whether the chosen estimate of effect by the
interquartile range increase in air pollution is
clinically relevant or not.
Other studies have found associations of
ambient air pollutants with FENO in elderly
adults with asthma (Jansen et al. 2005), adults
with cardiac disease (Adamkiewicz et al. 2004),
healthy adults (van Amsterdam et al. 1999),
and general populations of schoolchildren
(Fischer et al. 2002; Steerenberg et al. 2001,
2003). Our ﬁndings are most consistent with a
panel study of 19 asthmatic children in Seattle,
Washington (Koenig et al. 2003). In nine chil-
dren not taking ICS, they found an approxi-
mately 4-ppb increase in FENO per 10-µg/m3
lag 0 personal, indoor and outdoor home, and
ambient PM2.5. In a follow-up report of the
Seattle panel study, Koenig et al. (2005) found
that the estimated ambient-generated fraction
of personal PM2.5 exposure was positively asso-
ciated with FENO, but not the estimated
indoor-generated fraction. 
Results of models using distributed hourly
lags and daily average personal PM2.5 point to
Delfino et al.
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Table 6. Mixed-model estimates of associations between 2-day moving average personal and central-site air pollutant exposures and FENO stratiﬁed by medication use.
Not taking anti-inﬂammatory  Taking anti-inﬂammatory Inhaled corticosteroids  Antileukotrienes ± inhaled 
medications (14 subjects) medications (31 subjects) (19 subjects)a corticosteroids (12 subjects)b
Exposure Coefﬁcientc (95% CI) p-Value Coefﬁcient (95% CI) p-Value Coefﬁcient (95% CI) p-Value Coefﬁcient (95% CI) p-Value
Personal
PM2.5 1.11 (–1.39 to 3.60) 0.380 1.01 (0.19 to 1.84) 0.017 1.58 (0.72 to 2.43) 0.0004 –0.89 (–2.73 to 0.95)* 0.339
PM2.5 EC 0.84 (0.08 to 1.60) 0.031 0.71 (0.28 to 1.15) 0.001 0.67 (0.28 to 1.07) 0.001 0.03 (–3.29 to 3.35) 0.984
PM2.5 OC 0.88 (–1.62 to 3.38) 0.484 0.87 (–0.79 to 2.53) 0.302 2.47 (0.30 to 4.64) 0.026 0.52 (–1.99 to 3.02) 0.682
NO2 0.80 (–3.01 to 4.61) 0.677 1.67 (0.55 to 2.79) 0.004 1.22 (0.04 to 2.40) 0.043 1.73 (–0.70 to 4.16) 0.160
Central site
PM2.5 0.44 (–1.65 to 2.53) 0.677 0.55 (–0.47 to 1.57) 0.290 1.16 (0.11 to 2.20) 0.030 –0.75 (–2.83 to 1.32)* 0.471
PM10 0.76 (–1.54 to 3.07) 0.511 0.53 (–0.83 to 1.90) 0.439 1.28 (–0.01 to 2.58) 0.053 –2.10 (–5.33 to 1.12)* 0.196
PM2.5 EC 1.02 (–2.55 to 4.60) 0.570 1.42 (0.25 to 2.60) 0.018 1.28 (0.07 to 2.49) 0.038 1.15 (–1.58 to 3.88) 0.403
PM2.5 OC 0.36 (–4.07 to 4.79) 0.870 2.05 (0.24 to 3.86) 0.026 1.96 (0.14 to 3.78) 0.035 1.29 (–2.58 to 5.15) 0.508
NO2 0.96 (–1.34 to 3.26) 0.410 1.48 (0.47 to 2.50) 0.004 1.32 (0.33 to 2.32) 0.010 0.67 (–1.86 to 3.20) 0.598
aTwo subjects were also taking inhaled cromolyn. bTwo subjects were taking antileukotrienes only, and 10 were taking antileukotrienes plus inhaled corticosteroids. cThe expected
change in FENO associated with a 1-IQR change in each 2-day moving average air pollutant, adjusted for personal temperature, personal relative humidity, and run. IQR for personal air
pollutant measurements were 24 µg/m3 for PM2.5, 0.6 µg/m3 for PM2.5 EC, 4.1 µg/m3 for PM2.5 OC, and 17 ppb for NO2. IQR for central-site air pollutant measurements were 15 µg/m3 for
PM2.5, 23 µg/m3 for PM10, 0.8 µg/m3 for PM2.5 EC, 2.9 µg/m3 for PM2.5 OC, and 12 ppb for NO2. *p < 0.05 for difference with the coefﬁcient estimate for subjects taking inhaled corticos-
teroids but not antileukotriene medication.possible cumulative and lag effects (48-hr
mean and 1-day lag) and more immediate
effects (previous 5 hr) on FENO. Findings in
other panel studies also support a rapid effect
of recent hourly PM2.5 on biomarkers of
inflammation in children with asthma,
including the aforementioned Seattle study
using FENO (Mar et al. 2005), and a Denver,
Colorado, study using urinary leukotriene E4
(Rabinovitch et al. 2006). This may reflect
acute-phase inﬂammation from an early release
of mediators by mast and other cells, followed
by a late-phase response peaking a few hours
later and characterized by lymphocyte activa-
tion and infiltration (Hamid et al. 2003).
However, experimental data are needed to pro-
vide evidence that is more definitive for a
delayed (or cumulative) effect from multiday
exposures. 
The generally more robust associations for
personal than for central-site PM2.5 exposures
suggest that nondifferential exposure misclassiﬁ-
cation leads to attenuation of the particle associ-
ation and increased variance. This is graphically
demonstrated in Figure 3. A coherent contrast
between personal and ambient PM2.5 using
FEV1 as an outcome was found in our previous
asthma panel study (Delfino et al. 2004). In
addition, the present associations of FENO with
outdoor ambient EC and OC but not ambient
PM2.5 suggest that PM associations may be
missed using total particle mass measurements
alone, coherent with our previous ﬁndings for
ambient EC, OC, and symptoms in asthmatic
children in Los Angeles (Delﬁno et al. 2003).
Furthermore, the present significant associa-
tions of FENO with both personal and ambient
EC and NO2 suggest that despite potential mis-
classiﬁcation of personal exposure, ambient data
linked to combustion sources represents casual
pollutant components.
Air pollution and FENO in asthmatic children
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Figure 3. One- and two-pollutant models for change in FENO using 2-day MA personal (A) and central-site
(B) pollutant measurements. Squares: single-pollutant model; triangles: two-pollutants models. Expected
change in FENO is per IQR in the pollutant of interest with 95% CIs. All estimates are adjusted for personal
temperature and relative humidity.
Figure 2. Estimated lag effect of hourly personal PM2.5 on FENO by use of medications. (A) No anti-inﬂam-
matory medications. (B) Anti-inflammatory medications. (C) Inhaled corticosteroids. (D) Antileukotrienes
and inhaled corticosteroids. Estimates are based on a 4th-degree linear mixed-effects polynomial distrib-
uted lag model with AR(1) correlation structure. Expected changes in FENO correspond to a 1-IQR
(24 µg/m3) change in PM2.5. Blue bands indicate pointwise 95% CIs. Vertical dashes represent hourly
measurements. All estimates are adjusted for personal temperature and relative humidity.
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Figure 1. Estimated lag effect of hourly personal
PM2.5 on FENO. Estimates are based on a 4th-degree
linear mixed-effects polynomial distributed lag
model with AR(1) correlation structure. Expected
changes in FENO correspond to a 1-IQR (24 µg/m3)
change in PM2.5. Blue bands indicate pointwise 95%
CIs. Vertical dashes represent hourly measure-
ments. All estimates are adjusted for personal tem-
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models showed that EC and NO2 had the most
robust associations against inclusion of other
pollutants. However, in contrast to ambient
data, personal exposure models showed little to
no confounding of personal PM2.5 by EC or
NO2, suggesting that other causal factors in
personal PM exposures are not represented by
EC or NO2. Both EC and NO2 originate in
the study region largely from traffic-related
sources, which have high spatial variability
(Sioutas et al. 2005), thereby creating highly
variable personal exposures to EC and NO2 in
the present study population. Indoor concen-
trations represent the collective contributions of
local trafﬁc and other outdoor sources, as well
as indoor sources and activities, such as cook-
ing. Similarly, outdoor OC is dominated by
vehicular emissions and secondary organics,
whereas indoor OC includes contributions
from cooking and other sources of nontoxic
semivolatile OC, in addition to outdoor OC
that penetrates indoors. This, plus imprecision
of the personal monitor for OC, may have
increased misclassification of personal OC
exposure and weakened associations. Personal
PM2.5, on the other hand, likely represents a
variety of indoor particle components that can
induce asthma, including allergens and endo-
toxin (Rabinovitch et al. 2005). It also repre-
sents ambient PM2.5 given the moderate
correlation between ambient and personal
PM2.5 (R = 0.63, p < 0.001). Interaction
between personal PM2.5 and OC suggests a
possible interactive particle effect.
To assess further the potential contribution
of ambient air pollution to associations of FENO
with personal exposures, we tested two-pollu-
tant models with the same ambient and per-
sonal pollutant. Personal and ambient EC were
independently associated with FENO, whereas
personal NO2 confounded the association of
ambient NO2 with FENO. Lack of correlation
between personal and ambient EC suggests that
different sources contribute to the concentra-
tions. The moderate personal and ambient
NO2 correlation means that the same key
sources contribute to part of their concentra-
tions and perhaps to effects, which were best
captured by personal exposure measurements.
Among the ICS-only group, personal PM2.5
completely confounded ambient PM2.5 and
personal OC was similarly robust against ambi-
ent OC. Again, key sources were likely best
captured by personal exposures measurements.
In Supplemental Material (http://www.
ehponline.org/docs/2006/9141/suppl.pdf), we
present possible reasons for the personal versus
ambient pollutant findings in a preliminary
assessment of the relationship of personal to
indoor and outdoor home exposures.
There was no signiﬁcant difference in the
above associations between subjects taking anti-
inflammatory medications versus those who
were not. However, FENO was associated with
2-day average personal and ambient NO2, EC,
OC, and PM2.5, and ambient PM10, among
subjects taking ICS, but not in those taking a
combination of ICS and antileukotrienes.
Consistent differences were found for the last
5 hr of personal PM2.5 exposure. This suggests
a mixed pattern of susceptibility, because of
either treatment regimen or greater ongoing
asthma severity. Antileukotrienes are antagonists
of type 1 cysteinyl leukotriene receptors. They
are believed to have both anti-inﬂammatory as
well as bronchodilator effects on the airways
(Lipworth 1999). In a large clinical trial,
improvements in most clinical asthma control
measures occurred with either fluticasone or
montelukast; but outcomes, especially FENO,
improved signiﬁcantly more with ﬂuticasone
than with montelukast treatment (Zeiger et al.
2006). The greater response to air pollutants
despite medication suggests that the subjects
taking ICS may be more susceptible perhaps as
reﬂected by their persistent asthma. Persistent
asthma is a diagnostic indication of the need for
anti-inﬂammatory medication. The addition of
antileukotrienes may have achieved additional
control sufﬁcient to blunt responses to air pol-
lution exposures. Relevant experimental ﬁnd-
ings come from two clinical intervention
studies showing reduced respiratory responses
to air pollutants with montelukast treatment
(Gong et al. 2001; Rundell et al. 2005). In
addition, antileukotrienes are taken orally once
daily, whereas ICS are often prescribed as two
to four times per day and they require proce-
dures that are often not followed correctly.
Several other panel studies have found
adverse associations between asthma outcomes
and criteria air pollutants among subjects tak-
ing anti-inflammatory medications (Delfino
et al. 2003; Gent et al. 2003; Lewis et al. 2005;
Mortimer et al. 2000; Rabinovitch et al. 2006)
whereas other panel studies have shown larger
associations among subjects not taking any
anti-inﬂammatory medications (Delﬁno et al.
1998, 2002; Koenig et al. 2003, 2005; Mar
et al. 2005). It is conceivable that subjects not
taking anti-inflammatory medications who
have persistent asthma are more susceptible
than comparable subjects who take sufﬁcient
controller medications. Further investigation is
required to determine how the source and
composition of particle exposures contribute to
such differences in group susceptibility. 
These issues underlie two important limi-
tations of our study. First, we are reliant on
surrogate markers of pollutant components
(EC, OC, and NO2) and limited information
on sources. Second, the range of individual
mean FENO overlapped with concentrations
seen in healthy individuals, as previously
described (Buchvald et al. 2005). This issue is
tied to the still unresolved questions about
what FENO levels fully represent, and what the
between-individual determinants of FENO
levels are. Other perturbations besides inﬂam-
mation might increase NO release.
Conclusions
Exhaled NO in schoolchildren with asthma was
associated with personal and ambient back-
ground exposure to particulate air pollutants
and NO2. We found differences in association
by medication use, suggesting effect modiﬁca-
tion and pointing to the importance of assess-
ing individual susceptibility. We also conclude
that PM associations may be missed when
ambient mass-based methods are used alone,
which may not be sufﬁciently representative of
causal pollutant components for some popula-
tions or individuals. The relatively weak ﬁnd-
ings for ambient particle mass compared with
EC, OC, and NO2, suggest that protecting
public health may be insufﬁcient using only a
particle mass-based standard, as is currently the
case under the U.S. National Ambient Air
Quality Standards. Supplemental measure-
ments of particle composition and ultraﬁne par-
ticles (Sioutas et al. 2005), preferably on an
hourly scale, are needed to better assess the
health impact of particulate air pollution.
We found that association of FENO with
personal and ambient NO2 was largely inde-
pendent of personal and ambient EC and OC
fractions of PM2.5 in two-pollutant models,
suggesting that both ambient and personal
NO2 represents other causal pollutant compo-
nents not sufﬁciently captured by ambient EC
or OC in our study regions. In addition, NO2
is a potent oxidant, and experimental data sup-
port the hypothesis that oxidative stress may be
an important mechanism underlying NO2 toxi-
city (Persinger et al. 2002). To address this gap
in knowledge on causal components, continued
research is needed on toxic air pollutants
expected to have adverse respiratory effects
based on biologic mechanisms (e.g., oxidative
stress responses). There is also need for health
effects studies using source-speciﬁc as opposed
to a species-speciﬁc exposure assessments of air
pollution (Ebelt et al. 2005). These recommen-
dations are supported by our contrasting results
for personal versus ambient air pollution, espe-
cially the two-pollutant model showing inde-
pendence for personal versus ambient EC. The
different lag associations ranging from an
immediate FENO response to the preceding 5 hr
of PM2.5 to 2-day average PM2.5 also suggest
different sources and varying biologic mecha-
nisms are at play.
In addition to the relevance of the results
presented here to acute asthma exacerbations,
repeated insults from air pollutants may lead to
chronic adverse effects on childhood asthma.
There is evidence that persistent airway inﬂam-
mation in asthmatics leads to airway remodel-
ing, diminished lung growth, and permanent
lung function impairment (Fabbri et al. 1998).
Delfino et al.
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